These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

61 related articles for article (PubMed ID: 7831376)

  • 41. Monoclonal antiendotoxin agent HA-1A (Centoxin).
    Inglis TJ; Hawkey PM; Lacey RW; Bodeham A; Kay E; Calvert RT
    Lancet; 1993 Jan; 341(8840):303. PubMed ID: 8093933
    [No Abstract]   [Full Text] [Related]  

  • 42. Evaluating the cost containment potential of clinical guidelines.
    Carpenter CE; Nash DB; Johnson NE
    QRB Qual Rev Bull; 1993 Apr; 19(4):119-23. PubMed ID: 8493026
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cost-effectiveness analysis of the Dutch liver transplantation programme.
    Bonsel GJ; Klompmaker IJ; Essink-Bot ML; Habbema JD; Slooff MJ
    Transplant Proc; 1990 Aug; 22(4):1481-4. PubMed ID: 2117792
    [No Abstract]   [Full Text] [Related]  

  • 44. Novel monoclonal antiendotoxin antibody therapy: efficacy at any price?
    Fant WK
    Pharmacoeconomics; 1993 Jun; 3(6):437-45. PubMed ID: 10146878
    [No Abstract]   [Full Text] [Related]  

  • 45. A model for rational introduction of new and expensive medicines.
    Bell E; McCartney C
    Postgrad Med J; 1995 Feb; 71(832):86-9. PubMed ID: 7724440
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Another negative clinical trial of a new agent for the treatment of sepsis: rethinking the process of developing adjuvant treatments for serious infections.
    Fink MP
    Crit Care Med; 1995 Jun; 23(6):989-91. PubMed ID: 7774236
    [No Abstract]   [Full Text] [Related]  

  • 47. Looking back on HA-1A.
    Quezado ZM; Natanson C; Hoffman WD
    Arch Intern Med; 1994 Nov; 154(21):2393. PubMed ID: 7979833
    [No Abstract]   [Full Text] [Related]  

  • 48. Who should receive antiendotoxin monoclonal antibody therapy?
    Hardin TC; DiPiro JT
    Clin Pharm; 1992 Mar; 11(3):255-6. PubMed ID: 1611815
    [No Abstract]   [Full Text] [Related]  

  • 49. Increasing awareness of sepsis: World Sepsis Day.
    Vincent JL
    Crit Care; 2012 Sep; 16(5):152. PubMed ID: 22971299
    [No Abstract]   [Full Text] [Related]  

  • 50. Variation and Cost-effectiveness of Quality Measurement Programs. The Case of Sepsis Bundles.
    Wall MJ; Howell MD
    Ann Am Thorac Soc; 2015 Nov; 12(11):1597-9. PubMed ID: 26540416
    [No Abstract]   [Full Text] [Related]  

  • 51. The Effectiveness of NEPA.
    Culhane PJ
    Science; 1978 Dec; 202(4372):1034-6. PubMed ID: 17777937
    [No Abstract]   [Full Text] [Related]  

  • 52. The Effectiveness of NEPA.
    Liroff RA
    Science; 1978 Dec; 202(4372):1036-8. PubMed ID: 17777940
    [No Abstract]   [Full Text] [Related]  

  • 53. Novel pharmacologic approaches to the management of sepsis: targeting the host inflammatory response.
    Wheeler DS; Zingarelli B; Wheeler WJ; Wong HR
    Recent Pat Inflamm Allergy Drug Discov; 2009 Jun; 3(2):96-112. PubMed ID: 19519586
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The costs of septic syndromes in the intensive care unit and influence of hospital-acquired sepsis.
    Brun-Buisson C; Roudot-Thoraval F; Girou E; Grenier-Sennelier C; Durand-Zaleski I
    Intensive Care Med; 2003 Sep; 29(9):1464-71. PubMed ID: 12856120
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Cost-effectiveness analysis of human monoclonal antibody HA-1A in patients with sepsis syndrome].
    Van Hout BA; Rutten FF; Lorijn RH
    Ned Tijdschr Geneeskd; 1993 Feb; 137(7):360-4. PubMed ID: 8437635
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group.
    Ziegler EJ; Fisher CJ; Sprung CL; Straube RC; Sadoff JC; Foulke GE; Wortel CH; Fink MP; Dellinger RP; Teng NN
    N Engl J Med; 1991 Feb; 324(7):429-36. PubMed ID: 1988827
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cost-effectiveness of HA-1A monoclonal antibody for gram-negative sepsis. Economic assessment of a new therapeutic agent.
    Schulman KA; Glick HA; Rubin H; Eisenberg JM
    JAMA; 1991 Dec; 266(24):3466-71. PubMed ID: 1744962
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Gram-negative sepsis, the sepsis syndrome, and the role of antiendotoxin monoclonal antibodies.
    Barriere SL; Guglielmo BJ
    Clin Pharm; 1992 Mar; 11(3):223-35. PubMed ID: 1611812
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cost-effectiveness of HA-1A treatment for patients with sepsis.
    van Hout BA; Birnie E; Redekop WK; Lorijn RH; Bossuyt PM; Rutten FF
    Prog Clin Biol Res; 1994; 388():435-43. PubMed ID: 7831376
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.